Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Economic information and modeling reportBudget impact model

Perspective and time frame

3 evidence topics · 7 sources

Budget impact model of lirafugratinib: perspective and time frame

No evidence found.